Clinical Trial

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

Study to enroll 15 acute stroke patients across three U.S. sitesTEL AVIV, Israel and MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE)…

1 year ago

TeleDaaS™ Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations

TeleDaaS revolutionizes radiopharmaceutical research by delivering highly-scalable, clinical-grade dosimetry to accelerate cancer treatment breakthroughsCHICAGO, Nov. 26, 2023 (GLOBE NEWSWIRE) --…

1 year ago

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

BETHESDA, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the closing…

1 year ago

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and CAN10

LUND, SE / ACCESSWIRE / November 24, 2023 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new…

1 year ago

New Hope for Children: SciSparc’s patented CBD- Enhanced Solution for Autism Spectrum Disorder

TEL AVIV, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical…

1 year ago

Safety Shot Continues Scientific Development with Double-Blind Placebo-Controlled Trial Designed to Assess the Effects of Safety Shot on Blood and Breath Alcohol Levels

Topline data expected Q1 2024Safety Shot is designed to make you feel good faster by reducing blood alcohol levels and…

1 year ago

NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company”…

1 year ago

Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease

WINNIPEG, MB / ACCESSWIRE / November 23, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused…

1 year ago

Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule

ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion…

1 year ago

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS…

1 year ago